4zhvml8 发表于 2024-6-26 13:11:22

IF=39.397!肺癌“国创新药”舒沃替尼荣登Cancer Discovery,国内外顶级大咖高度点评来袭


    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;">医药魔方</a>——数据赋能医药创新,医药行业一站式大数据服务平台</p>
    <div style="color: black; text-align: left; margin-bottom: 10px;"><a style="color: black;"><span style="color: black;"><span style="color: black;">医药魔方</span><span style="color: black;"><span style="color: black;">​</span>%E2%80%8Bwww.pharmcube.com</span></span></a></div>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">近期</span>,我国自主<span style="color: black;">开发</span>、<span style="color: black;">日前</span>肺癌<span style="color: black;">行业</span>首个且<span style="color: black;">独一</span><span style="color: black;">得到</span>中、美两国“突破性疗法认定”的“I类新药”舒沃替尼再传捷报,其WU-KONG1和WU-KONG2<span style="color: black;">科研</span>在国际顶级期刊Cancer Discovery(IF 39.397)重磅<span style="color: black;">颁布</span>。</p>
    <div style="color: black; text-align: left; margin-bottom: 10px;"><img src="https://pic3.zhimg.com/80/v2-da4c7b6b923e04d5550f88326de5b312_720w.webp" style="width: 50%; margin-bottom: 20px;"></div>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">做为</span>针对EGFR突变非小细胞肺癌(NSCLC)设计的靶向新药,舒沃替尼<span style="color: black;">科研</span>能够被肿瘤<span style="color: black;">行业</span>影响因子排名<span style="color: black;">全世界</span>前十的国际顶刊收录,突显了迪哲医药在<span style="color: black;">药品</span><span style="color: black;">开发</span>、转化科学和临床<span style="color: black;">科研</span>上的<span style="color: black;">全世界</span>竞争力,<span style="color: black;">亦</span>创造了Cancer Discovery建刊<span style="color: black;">败兴</span>首篇以中国<span style="color: black;">科研</span>者为<span style="color: black;">第1</span>作者<span style="color: black;">发布</span>肺癌临床<span style="color: black;">科研</span>的佳绩。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">北京协和医院王孟昭教授和台湾大学医学院附设医院癌医中心分院杨志新教授是<span style="color: black;">文案</span><span style="color: black;">一起</span><span style="color: black;">第1</span>作者,美国哈佛大学医学院<span style="color: black;">附庸</span>丹娜法伯癌症<span style="color: black;">科研</span>院Pasi A. Jänne教授为本文通讯作者。本文特邀以上三位国内外知名学者,揭秘舒沃替尼独特的<span style="color: black;">药品</span>设计及出色的<span style="color: black;">科研</span>数据,并展望其临床应用前景。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">由独特<span style="color: black;">药品</span>设计到登顶国际顶刊,舒沃替尼展现国创新药明星<span style="color: black;">潜能</span></p>
    <div style="color: black; text-align: left; margin-bottom: 10px;"><img src="https://pic2.zhimg.com/80/v2-0a3122aa516646c3731da965204bd0d5_720w.webp" style="width: 50%; margin-bottom: 20px;"></div>
    <div style="color: black; text-align: left; margin-bottom: 10px;"><img src="https://pic1.zhimg.com/80/v2-ae19d210210b81a26994f96b09a007ec_720w.webp" style="width: 50%; margin-bottom: 20px;"></div>王孟昭教授,北京协和医院<span style="color: black;">呼气</span>内科<span style="color: black;">专家</span>,<span style="color: black;">专家</span>医师,博士生导师:非常开心看到舒沃替尼WU-KONG1和WU-KONG2<span style="color: black;">科研</span>成功<span style="color: black;">发布</span>于Cancer Discovery杂志上,这是所有参与本<span style="color: black;">科研</span>的<span style="color: black;">科研</span>者们、<span style="color: black;">病人</span>们<span style="color: black;">一起</span><span style="color: black;">奋斗</span>的结果。兼具转化<span style="color: black;">科研</span>成果和临床研究数据,舒沃替尼荣登国际顶刊<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Cancer Discovery<span style="color: black;">做为</span>AACR官方影响因子最高的期刊,和其他<span style="color: black;">大众</span>熟悉的顶级期刊,如JAMA Oncology、Lancet Oncology略有区别。Cancer Discovery这本杂志不仅关注临床<span style="color: black;">科研</span>,<span style="color: black;">亦</span>非常关注临床前<span style="color: black;">科研</span>、<span style="color: black;">研究</span>转化<span style="color: black;">科研</span>的成果。此次<span style="color: black;">发布</span>的舒沃替尼<span style="color: black;">科研</span>,不仅有I期<span style="color: black;">科研</span>结果,还<span style="color: black;">包含</span>了临床前<span style="color: black;">科研</span>数据,<span style="color: black;">例如</span>舒沃替尼的分子设计思路、药代动力学、药效学等<span style="color: black;">基本</span><span style="color: black;">科研</span>。</p>设计独特,展现优秀的疗效和安全性潜能<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">EGF</p>




m5k1umn 发表于 2024-10-1 12:42:27

外贸网站建设方法 http://www.fok120.com/

4zhvml8 发表于 2024-10-6 15:31:37

认真阅读了楼主的帖子,非常有益。
页: [1]
查看完整版本: IF=39.397!肺癌“国创新药”舒沃替尼荣登Cancer Discovery,国内外顶级大咖高度点评来袭